JPWO2023276869A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023276869A5
JPWO2023276869A5 JP2023531893A JP2023531893A JPWO2023276869A5 JP WO2023276869 A5 JPWO2023276869 A5 JP WO2023276869A5 JP 2023531893 A JP2023531893 A JP 2023531893A JP 2023531893 A JP2023531893 A JP 2023531893A JP WO2023276869 A5 JPWO2023276869 A5 JP WO2023276869A5
Authority
JP
Japan
Prior art keywords
inhibitor
igfbp
treatment
angiogenesis
angiogenesis inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531893A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023276869A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/025259 external-priority patent/WO2023276869A1/ja
Publication of JPWO2023276869A1 publication Critical patent/JPWO2023276869A1/ja
Publication of JPWO2023276869A5 publication Critical patent/JPWO2023276869A5/ja
Pending legal-status Critical Current

Links

JP2023531893A 2021-06-28 2022-06-24 Pending JPWO2023276869A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021106928 2021-06-28
PCT/JP2022/025259 WO2023276869A1 (ja) 2021-06-28 2022-06-24 血管新生阻害薬による治療後の予後予測方法および癌の併用療法

Publications (2)

Publication Number Publication Date
JPWO2023276869A1 JPWO2023276869A1 (https=) 2023-01-05
JPWO2023276869A5 true JPWO2023276869A5 (https=) 2025-05-09

Family

ID=84691826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531893A Pending JPWO2023276869A1 (https=) 2021-06-28 2022-06-24

Country Status (2)

Country Link
JP (1) JPWO2023276869A1 (https=)
WO (1) WO2023276869A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083391A2 (en) * 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
MX2013008833A (es) * 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
WO2012151574A1 (en) * 2011-05-05 2012-11-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
US11015190B2 (en) * 2013-09-17 2021-05-25 Lucence Life Sciences Pte Ltd Method of treating a patient having renal cancer
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor

Similar Documents

Publication Publication Date Title
Zhu et al. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
JP5750152B2 (ja) 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
Nel et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma
Furukawa et al. Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer
Wang et al. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer
Banys-Paluchowski et al. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer
Korse et al. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China
McAndrew et al. Effects of systemic inflammation on relapse in early breast cancer
Lu et al. Prognostic significance of increased preoperative red cell distribution width (RDW) and changes in RDW for colorectal cancer
Hetland et al. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Chen et al. eEF1A1 overexpression enhances tumor progression and indicates poor prognosis in hepatocellular carcinoma
Chen et al. Chromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer
Yan et al. A novel rapid quantitative method reveals stathmin‐1 as a promising marker for esophageal squamous cell carcinoma
Wu et al. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma
Ng Kee Kwong et al. Expression of PD‐L1 correlates with pleomorphic morphology and histological patterns of non‐small‐cell lung carcinomas
Fodor et al. Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study
Laloglu et al. Serum endocan levels in endometrial and ovarian cancers
Zhang et al. Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer
CN102625849A (zh) 侦测致死细胞的方法与材料及其应用
Ni et al. Detection of circulating tumour cells may add value in endometrial cancer management
Shim et al. Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma
Sugai et al. Vascular invasion and stromal S100A4 expression at the invasive front of colorectal cancer are novel determinants and tumor prognostic markers
Fujikura et al. Downregulation of 5‐hydroxymethylcytosine is an early event in pancreatic tumorigenesis
Wang et al. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
Byeon et al. Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy